fluticasone furoate/umeclidinium/vilanterol vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Reported efficacy
Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)
Result source: NCT02164513
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Reported efficacy
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)
Result source: NCT02184611
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Umeclidinium |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.9 vs 1.1vs FF/VINCT021645132 other results
| —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.0vs BUD/FORNCT0234516114 other results
| 0.1 vs -0.0+0.2 vs placeboNCT0218461121 other results
|
| SGRQ total, change | -6.6 vs -4.3vs BUD/FORNCT023451613 other results
| -6.2 vs -2.1−4 vs placeboNCT021526055 other results
|
| TDI focal score | 2.3 vs 1.7vs BUD/FORNCT023451611 other result
| 2.5 vs 1.6+0.9 vs placeboNCT02184611 |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- 0.9 vs 1.1vs FF/VINCT02164513
2 other results
- 0.2 vs 0.3 NCT02345161
- 0.2 vs 0.4 NCT02345161
- Umeclidinium
- —Trial running · NCT06474039
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs -0.0vs BUD/FORNCT02345161
14 other results
- 0.1 vs 0.1 NCT02729051
- 0.1 vs -0.1 NCT02345161
- 0.1 vs -0.0 NCT02164513
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs -0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.0 vs -0.0 NCT03478696
- 0.0 vs 0.0 NCT03478683
- Umeclidinium
- 0.1 vs -0.0+0.2 vs placeboNCT02184611
21 other results
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT02119286
- 0.1 vs -0.0 NCT02119286
- 0.2 vs 0.1 NCT02207829
- 0.2 vs 0.2 NCT02257385
- 0.1 vs 0.1 NCT02729051
- 0.2 vs 0.0 NCT02152605
- 0.2 vs 0.1 NCT01879410
- 0.1 vs -0.0 NCT02257372
- 0.1 vs -0.0 NCT03034915
- 0.1 vs 0.1 NCT02236611
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.2 vs -0.0 NCT02275052
SGRQ total, change
- fluticasone furoate/umeclidinium/vilanterol
- -6.6 vs -4.3vs BUD/FORNCT02345161
3 other results
- -4.6 vs -1.9 NCT02345161
- -5.5 vs -3.7 NCT02164513
- -5.8 vs -4.9 NCT02729051
- Umeclidinium
- -6.2 vs -2.1−4 vs placeboNCT02152605
5 other results
- -7.3 vs -4.3 NCT02184611
- -7.0 vs -2.5 NCT02184611
- -5.8 vs -1.4 NCT02184611
- -5.8 vs -4.9 NCT02729051
- -5.0 vs -3.3 NCT03034915
TDI focal score
- fluticasone furoate/umeclidinium/vilanterol
- 2.3 vs 1.7vs BUD/FORNCT02345161
1 other result
- 1.7 vs 1.4 NCT02345161
- Umeclidinium
- 2.5 vs 1.6+0.9 vs placeboNCT02184611
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 10 of 10 rows · Umeclidinium: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol Rows use multiple source trials | Umeclidinium Rows use multiple source trials |
|---|---|---|
| CAT responder rate · % of participants | 47.5% (n=1539) vs 39.9% (n=1543) Non-Ellipta @ 24wk*100 mcg/62.5 mcg/25 mcg by ELLIPTA DPIa,b,c Responders NCT03467425 · Phase 4 · registry result, not featured evidence · converted to % from 731 Participants as posted | 55% (n=812) vs 48% (n=804) UMEC @ 24wk62.5/25 mcga,b,c NCT03034915 · Phase 4 · registry result, not featured evidence |
| FEV1 Wm0 24 h absolute change · L | 0.039 vs 0.029 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcgd,e,b,c NCT03478696 · Phase 4 · registry result, not featured evidence show 1 more dose0.04 vs 0.023 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence | 0.213 vs 0.112 FSC L @ 12wk62.5/25 mcge,b,c NCT01879410 · Phase 3 · registry result, not featured evidence |
| SGRQ responder rate · % of participants | 50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25f,b,c NCT02729051 · Phase 3 · registry result, not featured evidence | 45% (n=811) vs 41% (n=802) UMEC @ 24wk62.5/25 mcgf,b,c NCT03034915 · Phase 4 · registry result, not featured evidence 1 other source trial50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| TDI Focal responder rate · % of participants | 56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25f,b,c NCT02729051 · Phase 3 · registry result, not featured evidence | 50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcgf,b,c NCT03034915 · Phase 4 · registry result, not featured evidence 1 other source trial56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| TDI Total absolute value · score | 2.029 vs 1.892 FF/VI + UMEC score @ 24wk100/62.5/25b,c NCT02729051 · Phase 3 · registry result, not featured evidence | 2.029 vs 1.892 FF/VI + UMEC score @ 24wk100/62.5/25b,c NCT02729051 · Phase 3 · registry result, not featured evidence |
| Time to First Moderate or Severe Exacerbation time to event · months | NA vs NA FF/VI + UMEC months100/62.5/25b,c,g NCT02729051 · Phase 3 · registry result, not featured evidence | NA vs NA FF/VI + UMEC months100/62.5/25b,c,g NCT02729051 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 10.5%FF/UMEC/VIh NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 4.9%100/62.5/25 µg NCT02345161 · Phase 3 6.1% NCT04923347 · Phase 4 · registry result, not featured evidence 9.5% NCT05535972 · Phase 4 · registry result, not featured evidence 3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 4.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.6%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 3.6%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 13.7%62.5 mcgi NCT02184611 · Phase 3 show 25 more results8.9%125 µg QD NCT01772147 · Phase 3 · combination 12.3%62.5 µg QD NCT01772147 · Phase 3 · combination 5.3%62.5 µg NCT01957163 · Phase 3 · combination 8.7%125 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT02119286 · Phase 3 · combination 5.3%62.5 µg NCT02119286 · Phase 3 · combination 10.7%125 µg QD NCT01772134 · Phase 3 · combination 6.9%62.5 µg QD NCT01772134 · Phase 3 · combination 11.7%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 5%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 8.4%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 8.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.6%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 7.3%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.9%FF/UMEC/VIh NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 1.8%100/62.5/25 µg NCT02345161 · Phase 3 — NCT04923347 · Phase 4 · registry result, not featured evidence 1.3% NCT05535972 · Phase 4 · registry result, not featured evidence 0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 1.5%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 0.3%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 1.4%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 2.4%62.5 mcgi NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 4.9%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 1.9%125 µg NCT01957163 · Phase 3 · combination 1%125 µg NCT02119286 · Phase 3 · combination 3.4%62.5 µg NCT02119286 · Phase 3 · combination 4.9%125 µg QD NCT01772134 · Phase 3 · combination 2.5%62.5 µg QD NCT01772134 · Phase 3 · combination 3.6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 1.9%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5.9%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 2%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 2.5%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —FF/UMEC/VIh NCT02164513 · Phase 3 show 9 more results21.6%100/62.5/25 NCT02164513 · Phase 3 6.7%100/62.5/25 µg NCT02345161 · Phase 3 0.4% NCT04923347 · Phase 4 · registry result, not featured evidence 4.1% NCT05535972 · Phase 4 · registry result, not featured evidence 7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 3.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.4%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 8%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence | 8.3%62.5 mcgi NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 3%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT01957163 · Phase 3 · combination 1.4%125 µg NCT02119286 · Phase 3 · combination 3.9%62.5 µg NCT02119286 · Phase 3 · combination 2.9%125 µg QD NCT01772134 · Phase 3 · combination 2%62.5 µg QD NCT01772134 · Phase 3 · combination 6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence 3%62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.4%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence 6.9%62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence 1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 100/62.5/25h viral upper respiratory tract infection 12.5% upper respiratory tract infection 7.2% headache 5.6% NCT02164513 · Phase 3 show 8 more resultsdysphonia 0.4% abdominal discomfort 0.2% abdominal pain upper 0.2% NCT05535972 · Phase 4 · registry result, not featured evidence 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI dyspnoea 2.1% NCT03467425 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 4.5% nasopharyngitis 4% NCT03474081 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 3.6% nasopharyngitis 1.9% NCT03478696 · Phase 4 · registry result, not featured evidence 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence | 62.5 mcgi upper respiratory tract infection 12.2% (placebo 12.9%) nasopharyngitis 9.3% (placebo 10.9%) dizziness 2.9% (placebo 2%) NCT02184611 · Phase 3 show 23 more results125 µg QD nasopharyngitis 5% (placebo 4.5%) headache 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.5%) nasopharyngitis 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg headache 4.4% (placebo 2.9%) back pain 3.4% (placebo 1.5%) nasopharyngitis 3.4% (placebo 3.4%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 4.8% (placebo 3.4%) headache 4.3% (placebo 2.9%) cough 3.4% (placebo 0.5%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 9.2% (placebo 10.7%) headache 1.9% (placebo 2.4%) back pain 1% (placebo 1.9%) NCT02119286 · Phase 3 · combination 62.5 µg nasopharyngitis 5.3% (placebo 10.7%) back pain 3.9% (placebo 1.9%) headache 3.9% (placebo 2.4%) NCT02119286 · Phase 3 · combination 125 µg QD headache 6.3% (placebo 4.9%) cough 2.4% (placebo 1.5%) nasopharyngitis 2.4% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.9%) cough 3.4% (placebo 1.5%) nasopharyngitis 2.5% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 mcg QD headache 8.1% nasopharyngitis 8.1% NCT02236611 · Phase 4 · registry result, not featured evidence 62.5 mcg+ICS/LABA nasopharyngitis 13.4% (placebo 14.5%) headache 3.4% (placebo 6.8%) cough 2.5% (placebo 4.3%) NCT02257372 · Phase 4 · registry result, not featured evidence · combination 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence 62.5 mcg QD headache 5.9% nasopharyngitis 5.3% NCT02207829 · Phase 3 · registry result, not featured evidence 62.5/25 µg headache 7.5% nasopharyngitis 6.6% cough 3.3% NCT02257385 · Phase 3 · registry result, not featured evidence 62.5/25mcg headache 6.5% (placebo 6.5%) nasopharyngitis 5.2% (placebo 6.5%) NCT02152605 · Phase 3 · registry result, not featured evidence 62.5/25 mcg headache 6.9% nasopharyngitis 4% NCT01879410 · Phase 3 · registry result, not featured evidence 62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThe reported result categories differ.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 4 versus Phase 3.
- fTrial phases differ: Phase 3 versus Phase 4.
- gThe assessment timepoint is not available for both results.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 2 more results
show 1 more result
show 17 more results
show 1 more result
show 1 more result
Umeclidinium
show 10 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 4 more results
+ 6 further endpoints in the CSV export.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT01573624 · Phase 2 · completed
The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.
Reported efficacy
Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)
Result source: NCT01573624
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/umeclidinium/vilanterol | Umeclidinium |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT04651777 | —Trial running · NCT04651777 |
| Trough FEV1, change | 0.1 vs 0.1vs FF/VINCT029246885 other results
| 0.3 vs 0.1+0.2 vs placeboNCT0301206117 other results
|
| ACQ-5, change | —Trial running · NCT04651777 | —Trial running · NCT04651777 |
| OCS dose reduction | —Trial running · NCT04651777 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Umeclidinium
- —Trial running · NCT04651777
Trough FEV1, change
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
- Umeclidinium
- 0.3 vs 0.1+0.2 vs placeboNCT03012061
17 other results
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.3 vs 0.1 NCT03012061
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.1 NCT02164539
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
ACQ-5, change
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Umeclidinium
- —Trial running · NCT04651777
OCS dose reduction
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Umeclidinium
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol | Umeclidinium |
|---|---|---|
| FEV1 Change 3 h absolute change · L | 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcga,b,c,d NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 3 more doses0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 | 0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QDa,b,c,d NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy show 1 more dose0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy |
| Dropout rate | 7.7%100/31.25/25 mcge NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | —100 mcg + 125 mcgf NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 5.1%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 6.5%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 5.8%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 0.7%100/31.25/25 mcge NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | —100 mcg + 125 mcgf NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 4.4%100/31.25/25 mcge NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination | 0%100 mcg + 125 mcgf NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results0%100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.6%100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0.7%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 2.9%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 2.2%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 100/31.25/25 mcge nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination | show 18 more results31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.25 mcg QD nasopharyngitis 10.1% (placebo 11.9%) headache 6.5% (placebo 7.7%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 62.5 mcg QD nasopharyngitis 9.4% (placebo 11.9%) headache 8.6% (placebo 7.7%) upper respiratory tract infection 4.3% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context differs: combination versus background therapy.
- ePopulation comparability has not been reviewed for 3 of these studies.
- fPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 1 more result
Umeclidinium
show 4 more results
show 4 more results
show 4 more results
show 6 more results
show 6 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Umeclidinium's landscape